Hairy cell leukemia: update and current therapeutic approach.
Hairy cell leukemia: update and current therapeutic approach.
复制标题
毛细胞白血病：更新和当前的治疗方法。
DOI：
10.1097/moh.0000000000000154
复制
发表时间：
2015
影响因子：
3.2
通讯作者：
Abdel-Wahab,Omar
中科院分区：
文献类型：
--
作者：
Salam,Latif;Abdel-Wahab,Omar
在近 100% 的 HCL 患者中鉴定出 BRAFV600E 突变，为将 BRAF 抑制剂纳入治疗方案中治疗 HCL 提供了依据。目前正在进行临床试验，测量维莫非尼在复发/难治性 HCL 中实现临床反应的功效以及毒性。其他使用单克隆和免疫毒素偶联抗体的新型疗法在最近的研究中也显示出有希望的反应。
Identification of the BRAFV600E mutation in nearly 100% of HCL patients has provided rationale for inclusion of BRAF inhibitors into the therapeutic armamentarium to treat HCL. Clinical trials are currently underway measuring efficacy of vemurafenib in achieving clinical response in relapsed/refractory HCL and also toxicity. Other novel therapies with monoclonal and immunotoxin-conjugated antibodies have also shown promising response in recent investigational studies.